Alexis Ogdie1, Lauren Harter2, Daniel Shin3, Joshua Baker4, Junko Takeshita5, Hyon K Choi6, Thorvardur Jon Love7, Joel M Gelfand5. 1. Division of Rheumatology, Center for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. 2. Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 3. Department of Dermatology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. 4. Division of Rheumatology, Philadelphia Veterans Administration Medical Center, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. 5. Department of Dermatology, Center for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. 6. Division of Rheumatology and Allergy/Immunology, Massachusetts General Hospital, Boston, Massachusetts, USA. 7. Division of Rheumatology, Landspitali University Hospital, University of Iceland, Reykjavik, Iceland.
Abstract
OBJECTIVE: To determine the risk of fracture and osteoporosis among patients with psoriatic arthritis (PsA) and psoriasis, compared with the general population and patients with rheumatoid arthritis (RA). METHODS: A population-based cohort study was performed in The Health Improvement Network in the UK using data from 1994 to 2014. Patients aged 18-89 years with PsA or psoriasis and up to five unexposed controls matched by practice and start date within that practice were included. Patients with RA and matched controls were included for comparison. Severe psoriasis was defined by a code for psoriasis and either phototherapy or a systemic medication for psoriasis. Incidence and adjusted HRs (aHR) for fracture (all, hip, vertebral) were calculated. RESULTS: Patients with PsA (n=9788), psoriasis (n=158 323) and controls (n=821 834) were identified. Patients with PsA had an elevated risk of all fracture aHR 1.26 (1.06 to 1.27). Patients with mild psoriasis had elevated risk of all fractures, vertebral and hip fracture: aHR 1.07 (1.05 to 1.10), 1.17 (1.03 to 1.33) and 1.13 (1.04 to 1.22). Patients with severe psoriasis had significantly elevated risk of all fracture and vertebral fracture: aHR 1.26 (1.15 to 1.39) and 2.23 (1.54 to 3.22). CONCLUSIONS: PsA and psoriasis are associated with an elevated risk for fracture. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
OBJECTIVE: To determine the risk of fracture and osteoporosis among patients with psoriatic arthritis (PsA) and psoriasis, compared with the general population and patients with rheumatoid arthritis (RA). METHODS: A population-based cohort study was performed in The Health Improvement Network in the UK using data from 1994 to 2014. Patients aged 18-89 years with PsA or psoriasis and up to five unexposed controls matched by practice and start date within that practice were included. Patients with RA and matched controls were included for comparison. Severe psoriasis was defined by a code for psoriasis and either phototherapy or a systemic medication for psoriasis. Incidence and adjusted HRs (aHR) for fracture (all, hip, vertebral) were calculated. RESULTS:Patients with PsA (n=9788), psoriasis (n=158 323) and controls (n=821 834) were identified. Patients with PsA had an elevated risk of all fracture aHR 1.26 (1.06 to 1.27). Patients with mild psoriasis had elevated risk of all fractures, vertebral and hip fracture: aHR 1.07 (1.05 to 1.10), 1.17 (1.03 to 1.33) and 1.13 (1.04 to 1.22). Patients with severe psoriasis had significantly elevated risk of all fracture and vertebral fracture: aHR 1.26 (1.15 to 1.39) and 2.23 (1.54 to 3.22). CONCLUSIONS: PsA and psoriasis are associated with an elevated risk for fracture. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: James D Lewis; Rita Schinnar; Warren B Bilker; Xingmei Wang; Brian L Strom Journal: Pharmacoepidemiol Drug Saf Date: 2007-04 Impact factor: 2.890
Authors: B Frediani; A Allegri; P Falsetti; L Storri; S Bisogno; F Baldi; P Filipponi; R Marcolongo Journal: J Rheumatol Date: 2001-01 Impact factor: 4.666
Authors: Lia Gutiérrez; Neil Roskell; Jordi Castellsague; Stephen Beard; Catherine Rycroft; Shaun Abeysinghe; Paul Shannon; Sean Robbins; Matthew Gitlin Journal: J Med Econ Date: 2011-01-11 Impact factor: 2.448
Authors: Lia Gutiérrez; Neil Roskell; Jordi Castellsague; Steve Beard; Catherine Rycroft; Shaun Abeysinghe; Paul Shannon; Matthew Gitlin; Sean Robbins Journal: Bone Date: 2012-06-06 Impact factor: 4.398
Authors: Soumya M Reddy; Allen P Anandarajah; Mark C Fisher; Philip J Mease; Jeffrey D Greenberg; Joel M Kremer; George Reed; Rui Chen; Susan Messing; Kimberly Kaukeinen; Christopher T Ritchlin Journal: J Rheumatol Date: 2010-09-15 Impact factor: 4.666
Authors: Lu Yang; Melania H Fanok; Aranzazu Mediero-Munoz; Laura K Fogli; Carmen Corciulo; Shahla Abdollahi; Bruce N Cronstein; Jose U Scher; Sergei B Koralov Journal: Arthritis Rheumatol Date: 2018-04-18 Impact factor: 10.995
Authors: Z Paskins; R Whittle; A Abdul Sultan; S Muller; M Blagojevic-Bucknall; T Helliwell; J Packham; S Hider; E Roddy; C Mallen Journal: Osteoporos Int Date: 2018-03-24 Impact factor: 4.507